We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Lens Method Analyzes Tears for Early Disease Detection

By LabMedica International staff writers
Posted on 20 Dec 2024

Bodily fluids, including tears and saliva, carry proteins that are released from different parts of the body. More...

The presence of specific proteins in these biofluids can be a sign of health issues. Tears, in particular, are well-suited for detecting eye diseases such as glaucoma and macular degeneration, but they can also help identify systemic conditions like breast cancer and Alzheimer's disease. The challenge, however, is that collecting tears is difficult. Existing tear sampling methods can be uncomfortable, irritating to the eye, and typically yield reflex tears, which are less useful for disease detection. Now, researchers have developed an innovative technique using soft contact lenses to collect proteins from basal tears, offering a more efficient method for early disease detection.

While reflex tears are easily triggered by irritation, they are unlikely to contain the proteins needed for disease detection. These tears would dilute the indicator proteins that could point to a health issue. To avoid this, researchers at Brigham Young University (Provo, UT, USA) proposed a gentler approach: using soft contact lenses that naturally absorb proteins from the eye. Their tests showed that lenses made from the hydrogel material Etafilcon-A collected the highest protein levels without causing irritation.

In experiments, volunteers wore the contact lenses for just five minutes, and the lenses absorbed nearly the same range of proteins as traditional methods, but with significantly less discomfort. This new approach, as described in the study published in Clinical Proteomics, also allows patients to collect their own tears, removing the need for a trained optometrist. The research team is currently conducting further clinical trials to link specific tear proteins with diseases like macular degeneration and cancer. Their long-term goal is to make this method available in optometrists' and oncologists' offices, providing an easy and non-invasive way to detect early signs of various conditions.

“How many people could be helped if doctors could catch diseases before symptoms develop? With this new lens method, we could potentially screen for a range of health issues from analyzing tears,” said former grad student Robert Roden. “This project is very powerful in its scope. Any disease that your blood touches has the potential to show up in your tears. Hopefully this sampling can turn into a routine screening.”


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Parainfluenza Virus Test
PARAINFLUENZA ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.